Outcomes of GLP-1 Receptor Agonist Therapy in Adults with Sickle Cell Disease and Type 2 Diabetes: A Real-World Cohort Analysis
Nguefang GL, Boateng S, Gyabaah S, Issaka Y, Konlack JG, Landa EL, Eze E, Njei B
Summary
This real-world study of 1,391 propensity-matched pairs found that GLP-1 receptor agonist therapy in adults with both sickle cell disease and type 2 diabetes was associated with a 39% lower risk of major adverse cardiovascular events (HR 0.61, p<0.00001), a 53% reduction in stroke risk (HR 0.47, p=0.036), and a 36% lower risk of vaso-occlusive crises (HR 0.64, p=0.013). Importantly, there was no increased risk of hypoglycemia.
Clinical Significance
This is among the first studies to evaluate GLP-1 RAs specifically in sickle cell disease patients — a high-risk population with significant cardiovascular burden. The finding that GLP-1 therapy may reduce vaso-occlusive crises opens a new therapeutic avenue beyond glycemic control for this underserved population.
Key Findings
- Population: 1,391 propensity-matched pairs with SCD + T2DM (84% Black)
- Primary outcome: 39% lower MACE risk with GLP-1 RA therapy
- Stroke: 53% risk reduction (HR 0.47)
- Vaso-occlusive crises: 36% reduction — novel finding suggesting vasculoprotective benefits
- Safety: No difference in hypoglycemia or CKD progression
Clinical Implications
The vaso-occlusive crisis reduction is particularly noteworthy, as it suggests GLP-1 RAs may stabilize endothelial function and reduce inflammation in sickle cell disease. This extends the therapeutic value of GLP-1 RAs beyond metabolic disease into hematology.
関連研究
Determinants of VO2peak Responsiveness to Aerobic Exercise Training in Adults with Type 2 Diabetes: The PROTECTION Study
In 108 adults with Type 2 diabetes participating in a 26-week supervised cycling programme, GLP-1 re…
Association of Dual SGLT-2 Inhibitor and GLP-1 Receptor Agonist Therapy with Colon Cancer Risk in Post-Polypectomy Patients with Diabetes: A Target Trial Emulation
This target trial emulation study examined whether dual SGLT-2 inhibitor and GLP-1 receptor agonist …
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis evaluated the association between GLP-1 receptor agonist use and de…
GLP-1 Receptor Agonist Therapy in Adults With Sickle Cell Disease and Type 2 Diabetes: A Real-World Cohort Analysis
This real-world study of 1,391 matched patients with sickle cell disease (SCD) and type 2 diabetes f…